Digirad has received FDA clearance for expanded use of its ergo imaging system. The broader clearance covers lymphatic scintigraphy and parathyroid scintigraphy for evaluation of lesions in the breast and elsewhere in the body. The device was first cleared three years ago by the FDA.
FDA OKs broader use of ergo imaging system
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan